Aytu BioPharma Statistics
Total Valuation
Aytu BioPharma has a market cap or net worth of $8.49 million. The enterprise value is $6.56 million.
Important Dates
The next estimated earnings date is Wednesday, February 12, 2025, after market close.
| Earnings Date | Feb 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Aytu BioPharma has 6.15 million shares outstanding. The number of shares has increased by 39.29% in one year.
| Current Share Class | 6.15M |
| Shares Outstanding | 6.15M |
| Shares Change (YoY) | +39.29% |
| Shares Change (QoQ) | +61.92% |
| Owned by Insiders (%) | 2.71% |
| Owned by Institutions (%) | 7.49% |
| Float | 4.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 2.35 |
| PS Ratio | 0.10 |
| Forward PS | 0.15 |
| PB Ratio | 0.28 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.08 |
| EV / EBITDA | 1.02 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.99, with a Debt / Equity ratio of 0.61.
| Current Ratio | 0.99 |
| Quick Ratio | 0.71 |
| Debt / Equity | 0.61 |
| Debt / EBITDA | 2.17 |
| Debt / FCF | n/a |
| Interest Coverage | -0.32 |
Financial Efficiency
Return on equity (ROE) is -23.48% and return on invested capital (ROIC) is -1.87%.
| Return on Equity (ROE) | -23.48% |
| Return on Assets (ROA) | -0.72% |
| Return on Capital (ROIC) | -1.87% |
| Revenue Per Employee | $781,951 |
| Profits Per Employee | -$61,275 |
| Employee Count | 102 |
| Asset Turnover | 0.64 |
| Inventory Turnover | 2.06 |
Taxes
In the past 12 months, Aytu BioPharma has paid $2.17 million in taxes.
| Income Tax | 2.17M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -52.25% in the last 52 weeks. The beta is -1.42, so Aytu BioPharma's price volatility has been lower than the market average.
| Beta (5Y) | -1.42 |
| 52-Week Price Change | -52.25% |
| 50-Day Moving Average | 1.78 |
| 200-Day Moving Average | 2.54 |
| Relative Strength Index (RSI) | 33.73 |
| Average Volume (20 Days) | 37,245 |
Short Selling Information
The latest short interest is 118,397, so 1.93% of the outstanding shares have been sold short.
| Short Interest | 118,397 |
| Short Previous Month | 120,797 |
| Short % of Shares Out | 1.93% |
| Short % of Float | 2.69% |
| Short Ratio (days to cover) | 10.45 |
Income Statement
In the last 12 months, Aytu BioPharma had revenue of $79.76 million and -$6.25 million in losses. Loss per share was -$1.61.
| Revenue | 79.76M |
| Gross Profit | 54.26M |
| Operating Income | -1.44M |
| Pretax Income | -12.61M |
| Net Income | -6.25M |
| EBITDA | 6.42M |
| EBIT | -1.44M |
| Loss Per Share | -$1.61 |
Full Income StatementBalance Sheet
The company has $20.11 million in cash and $18.19 million in debt, giving a net cash position of $1.92 million or $0.31 per share.
| Cash & Cash Equivalents | 20.11M |
| Total Debt | 18.19M |
| Net Cash | 1.92M |
| Net Cash Per Share | $0.31 |
| Equity (Book Value) | 29.83M |
| Book Value Per Share | 4.85 |
| Working Capital | -514,000 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$2.37 million and capital expenditures -$136,000, giving a free cash flow of -$2.50 million.
| Operating Cash Flow | -2.37M |
| Capital Expenditures | -136,000 |
| Free Cash Flow | -2.50M |
| FCF Per Share | -$0.41 |
Full Cash Flow StatementMargins
Gross margin is 68.03%, with operating and profit margins of -1.80% and -7.84%.
| Gross Margin | 68.03% |
| Operating Margin | -1.80% |
| Pretax Margin | -6.40% |
| Profit Margin | -7.84% |
| EBITDA Margin | 8.05% |
| EBIT Margin | -1.80% |
| FCF Margin | n/a |